ZA200905636B - Stable antibody formulations - Google Patents

Stable antibody formulations

Info

Publication number
ZA200905636B
ZA200905636B ZA200905636A ZA200905636A ZA200905636B ZA 200905636 B ZA200905636 B ZA 200905636B ZA 200905636 A ZA200905636 A ZA 200905636A ZA 200905636 A ZA200905636 A ZA 200905636A ZA 200905636 B ZA200905636 B ZA 200905636B
Authority
ZA
South Africa
Prior art keywords
antibody formulations
stable antibody
stable
formulations
antibody
Prior art date
Application number
ZA200905636A
Other languages
English (en)
Inventor
Arvind Srivastava
Joel Goldstein
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of ZA200905636B publication Critical patent/ZA200905636B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200905636A 2007-03-22 2009-08-13 Stable antibody formulations ZA200905636B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91974407P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
ZA200905636B true ZA200905636B (en) 2010-10-27

Family

ID=39766776

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905636A ZA200905636B (en) 2007-03-22 2009-08-13 Stable antibody formulations

Country Status (18)

Country Link
US (1) US20100260766A1 (ru)
EP (1) EP2136839A4 (ru)
JP (1) JP2010522208A (ru)
KR (1) KR20090113340A (ru)
CN (1) CN101668540A (ru)
AU (1) AU2008228823A1 (ru)
BR (1) BRPI0809112A2 (ru)
CA (1) CA2681743A1 (ru)
CR (1) CR11005A (ru)
DO (1) DOP2009000222A (ru)
EA (1) EA200970880A1 (ru)
EC (1) ECSP099642A (ru)
IL (1) IL200321A0 (ru)
MX (1) MX2009010179A (ru)
TN (1) TN2009000382A1 (ru)
UA (1) UA96473C2 (ru)
WO (1) WO2008116103A2 (ru)
ZA (1) ZA200905636B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
TW200838559A (en) * 2006-11-29 2008-10-01 Imclone Systems Inc Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2010056550A1 (en) 2008-10-29 2010-05-20 Wyeth Llc Methods for purification of single domain antigen binding molecules
CN102271707B (zh) 2008-10-29 2015-04-08 阿布林克斯公司 单域抗原结合性分子的制剂
US20110293605A1 (en) * 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
SG188487A1 (en) 2010-09-17 2013-05-31 Baxter Int Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
KR20180129991A (ko) 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
KR102091294B1 (ko) * 2011-10-26 2020-04-16 암젠 인크 Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP2016505601A (ja) 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EA202190808A2 (ru) 2015-11-03 2021-12-31 Янссен Байотек, Инк. Составы антител к cd38 для подкожного введения и их применение
JP6992262B2 (ja) * 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
CA2451955C (en) * 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
KR101080021B1 (ko) * 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
MXPA05008617A (es) * 2003-02-13 2005-11-04 Pfizer Prod Inc Usos de anticuerpos anti-receptor del factor de crecimiento semejante a la insulina i.
EP1622942B1 (en) * 2003-05-01 2014-11-19 ImClone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
MX2007014148A (es) * 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
WO2006138315A2 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-igf1r antibody formulations
KR20080104160A (ko) * 2006-03-28 2008-12-01 에프. 호프만-라 로슈 아게 항-ｉｇｆ-１ｒ 인간 단일클론 항체 제형

Also Published As

Publication number Publication date
DOP2009000222A (es) 2009-12-15
ECSP099642A (es) 2009-11-30
CN101668540A (zh) 2010-03-10
CR11005A (es) 2010-08-05
WO2008116103A3 (en) 2009-01-08
EP2136839A2 (en) 2009-12-30
UA96473C2 (ru) 2011-11-10
AU2008228823A1 (en) 2008-09-25
EA200970880A1 (ru) 2010-02-26
BRPI0809112A2 (pt) 2014-08-26
KR20090113340A (ko) 2009-10-29
TN2009000382A1 (en) 2010-12-31
WO2008116103A2 (en) 2008-09-25
JP2010522208A (ja) 2010-07-01
IL200321A0 (en) 2010-04-29
CA2681743A1 (en) 2008-09-25
EP2136839A4 (en) 2010-04-07
MX2009010179A (es) 2010-03-15
US20100260766A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
HRP20182146T1 (hr) Formulacije protutijela natalizumab
IL200321A0 (en) Stable antibody formulations
HK1214947A1 (zh) 抗體製劑
EP2173163A4 (en) ANTIBODY FORMULATIONS
EP2077859A4 (en) ANTIBODY FORMULATION
SG10201604258YA (en) Anti-tnf antibody formulations
GB0711656D0 (en) Formulations
GB0716385D0 (en) Formulations
ZA200908969B (en) Formulations
GB0711957D0 (en) Formulations
GB0809979D0 (en) Formulations
GB0810232D0 (en) Formulations
EP2167635A4 (en) ANTIBODY FORMULATIONS
GB0705179D0 (en) Formulations
GB0710346D0 (en) Formulations
GB0713886D0 (en) Formulations
GB0708663D0 (en) Formulations
GB0701993D0 (en) Formulations
GB0710350D0 (en) Formulations
GB0710900D0 (en) Formulations